Inhibitory effects and mechanism of 5-fluorouracil combined with celecoxib on human gastric cancer xenografts in nude mice

Abstract

5-Fluorouracil (5-Fu) is one of the most commonly used drugs to treat gastric cancer; however, drug-resistance in cancer cells reduces the efficacy of 5-Fu. Celecoxib may be able to reduce resistance to 5-Fu chemotherapy. The aim of the present study was to investigate the inhibitory effects of a combination of 5-Fu and celecoxib on implanted gastric cancer xenografts in nude mice and to elucidate the underlying mechanism. A tumor-bearing nude mice model was established. The mice were divided into blank control, 5-Fu, celecoxib and combination groups. The weight change and the tumor inhibition rate in each group were calculated. Immunocytochemistry, reverse transcription-polymerase chain reaction and western blotting methods were used to observe hypoxia-inducible factor-2α (HIF-2α), ATP-binding cassette transporter G2 (ABCG2) and octamer-binding transcription factor 4 (Oct-4) expression in the SGC7901 cells. Inhibition of the growth of the implanted gastric cancer was observed in the 5-Fu, celecoxib and combination groups. In the celecoxib and combination treatment groups, the mean tumor mass was significantly less than that in the control group (P<0.05), and the mean tumor mass in the combination treatment group was significantly less than that in the 5-Fu group (P<0.05). The tumor inhibition rates in the 5-Fu, celecoxib and combination groups were 26.36, 59.70 and 88.37%, respectively. The combination group exhibited the highest inhibition rate; the inhibition rates of the combination and celecoxib groups were significantly higher compared with the 5-Fu group (P<0.05). The expression levels of HIF-2, ABCG2 and Oct-4 mRNA and protein were high in the blank control group, and were further increased in the 5-Fu group. However, in the celecoxib and combination groups, the expression levels were lower compared with those in the control group. Significant differences were identified among the 5-Fu, celecoxib and combination groups (P<0.01). Celecoxib has antitumor effects in vivo. The mechanism may be associated with the reduced expression of cancer stem cell markers HIF-2α, Oct-4 and ABCG2. 5-Fu and celecoxib have a synergistic antitumor effect. The mechanism associated with the amelioration of resistance to chemotherapy in gastric cancer and the enhancement of the effect of chemotherapy may be via the reduction of the expression of HIF-2α, ABCG2, Oct-4 and other cancer stem cell markers in the tumor tissues.

Biocompatible Fe-Based Micropore Metal-Organic Frameworks as Sustained-Release Anticancer Drug Carriers

“…The second highest mortality rate in humans among all kinds of diseases is due to malignant tumors. Liver cancer is the third most common cancer [ 1 ]. The treatment of liver cancer primarily involves high doses of chemotherapy and surgical treatment.…”

Combinatorial therapeutic approach for treatment of oral squamous cell carcinoma

“…PTX promotes its anticancer activity by acting on the microtubules during the mitotic phase and thus enhances the polymerization of the tubulin; microtubules thus formed in its presence have unusual stability and thus it resists the depolymerization [14]. 5-Fluorouracil (5-FU) is an anti-metabolite antitumour drug and it interferes with nucleic acid and DNA synthesis resulting in cell apoptosis [15]. It is mostly used for the treatment of several solid tumours including colorectal, breast, liver and pancreatic cancer alone or in combination with other drugs [16].…”

Diallyl trisulfide inhibits gastric cancer stem cell properties through ΔNp63/sonic hedgehog pathway

“…Gastric cancer cells with ALDH + exhibited higher CSC traits including tumorigenic and clonogenic properties compared with ALDH − gastric cells 29 . Moreover, pluripotent stem cell factors, such as Oct 4 and Nanog, also are concerned with the regulation of gastric CSC characteristics 7,30 . In addition, CSCs exhibited self‐renewal capacity.…”